January 2026
1. FEARON WF, Terada K, Takahashi K, Skoda A, et al
   Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
   Circulation. 2026;153:7-17.
   

   >> Share

   
   August 2025
2. LIU Y, Wang H, Yu M, Cai L, et al
   Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.
   Circulation. 2025 Aug 5:10.1161/CIRCULATIONAHA.125.074737.
   

   >> Share

   
   May 2025
3. WIEGMAN A, Peterson AL, Hegele RA, Bruckert E, et al
   Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
   Circulation. 2025 May 20. doi: 10.1161/CIRCULATIONAHA.124.073233.
   

   >> Share

   
   January 2025
4. CHEW NWS, Mehta A, Goh RSJ, Zhang A, et al
   Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.
   Circulation. 2025;151:98-119.
   

   >> Share

   
   August 2024
5. DAMASE TR, Sukhovershin R, Godin B, Nasir K, et al
   Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
   Circulation. 2024;150:724-735.
   

   >> Share

   
   April 2024
6. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
   HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
   Circulation. 2024;149:1183-1201.
   

   >> Share

   
   February 2024
7. STONE NJ, Blum C
   If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
   Circulation. 2024;149:427-429.
   

   >> Share

   
   January 2024
8. SANTOS RD, Cuchel M
   LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
   Circulation. 2024;149:363-366.
   

   >> Share

   
   November 2023
9. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
   BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
   Circulation. 2023;148:1764-1777.
   

   >> Share

   
   
10. MILES J, Scotti A, Castagna F, Kuno T, et al
    Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
    Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
    

    >> Share

    
    October 2023
11. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
    

    >> Share

    
    
12. RAAL F, Durst R, Bi R, Talloczy Z, et al
    Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
    

    >> Share

    
    September 2023
13. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
    Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1057.
    

    >> Share

    
    
14. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
    Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1059-1060.
    

    >> Share

    
    
15. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    

    >> Share

    
    July 2023
16. LAGU T, Schroth SL, Haywood C, Heinemann A, et al
    Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review.
    Circulation. 2023;148:268-277.
    

    >> Share

    
    
17. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    

    >> Share

    
    May 2023
18. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    

    >> Share

    
    April 2023
19. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share